Showing 3741-3750 of 5660 results for "".
- High Doses of Sunshine Vitamin May Improve Sunburnhttps://practicaldermatology.com/news/high-doses-of-sunshine-vitamin-may-improve-sunburn/2458128/High doses of vitamin D taken one hour after sunburn may significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- Foamix Pharmaceuticals Appoints David Domzalski as CEOhttps://practicaldermatology.com/news/foamix-pharmaceuticals-appoints-david-domzalski-as-ceo/2458137/Foamix Pharmaceuticals Ltd.'s Board of Directors has named David Domzalski Chief Executive Officer of the company effective immediately. Mr. Domzalski currently serves as President of Foamix's US subsidiary. He succeeds Dr. Dov
- Coppertone Whips Up Excitement About New Sunscreen Linehttps://practicaldermatology.com/news/coppertone-whips-up-excitement-about-new-sunscreen-line/2458152/Coppertone is going all out to launch their new Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, including partnering with beauty influencers and the Skin Cancer Foundation. The brand is promot
- May 26, 2017 is Don't Fry Dayhttps://practicaldermatology.com/news/may-26-2017-is-dont-fry-day/2458173/The Friday before Memorial Day (May 26, 2017) is Don’t Fry Day. The day, designated by the American Society for Dermatologic Surgery Association (ASDSA) in collaboration with
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Statement from AAD President Henry W. Lim, MD, FAAD, on the Safety of Sunscreenhttps://practicaldermatology.com/news/statement-from-aad-president-henry-w-lim-md-faad-on-the-safety-of-sunscreen/2458179/“The American Academy of Dermatology wants to emphasize that sunscreen remains a safe, effective form of sun protection. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cance
- DerMend's New Line Takes On Mature Skin Issueshttps://practicaldermatology.com/news/dermends-new-line-takes-on-mature-skin-issues/2458190/DerMend® is launching DerMend® Mature Skin Solutions. The new product line features DerMend®Fragile Skin Moisturizing Formula, DerMend® Moisturizing Anti-Itch Lotion and DerMend® Moisturizing Bruise Formu
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to